Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 518-530

  Hussein, Ziad ^a   Eaves, Jane ^b   Hutchinson, David B ^b   Canfield, Craig J ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; PROGUANIL; PYRIMETHAMINE;

ADOLESCENT; ADULT; ARTICLE; ASIAN; BODY WEIGHT; CHILD; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; META ANALYSIS; NEGRO; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; POPULATION; PRIORITY JOURNAL; RACE DIFFERENCE; TABLET;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIMALARIALS; ATOVAQUONE; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABON; HUMANS; KENYA; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NAPHTHOQUINONES; PHILIPPINES; THAILAND; ZAMBIA;

EID: 0030909429     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90132-6     Document Type: Article

References (23)

1. Wyler DJ. Malaria-resurgence, resistance and research. N Engl J Med 1983;308:875-8, 934-40.
2. Falloon J, Kovacs J, Hughes W, O'Neill D, Polis M, Davey RT Jr, et al. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with acquired immunodeficiency syndrome. New Engl J Med 1991;28:1534-8.
3. Dohn MN, Frame PT, Baughman RP, Lafon SW, Smulian AG, Caldwell P, et al. Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients. J Protozool 1991; 38(suppl):220S-1S.
4. Hughes WT, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-7.
5. Epstein LJ, Mohsenifar Z, Daar ES, Yeh V, Meyer RD. Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia. Am J Med Sci 1994;308:5-8.
6. Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med 1994;121:174-80.
7. Peters BS, Carlin E, Weston RJ, Loveless SJ, Sweeney J, Weber J, et al. Adverse effects of drugs in the management of opportunistic infections associated with HIV infection. Drug Saf 1994;10:439-54.
8. Stoeckle M, Tennenberg A. Atovaquone for Pneumocystis carinii pneumonia [letter, comment]. Ann Intern Med 1995;122:314-5.
9. Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993;27:1488-94.
10. Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, et al. Safety and pharmacokinetics of 566C88, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis 1991;163:843-8.
11. Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DB, et al. 566C80: a potent spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991;17:427-35.
12. Ittarat I, Asawamahasakda, Meshnick SR. The effects of antimalarials on Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol 1994;79:50-6.
13. Blanchard TJ, Mabey DC, Hunt-Cooke A, Edwards G, Hutchinson DB, Benjamin S, et al. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg 1994;88:693.
14. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80:373-81.
15. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone and in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-6.
16. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994;37:13-20.
17. Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996;40:556-60.
18. Lavelle J, Trapnell C, Byrne R, Noblin J, Sadler B, Blum R, et al. The absolute bioavailability of atovaquone tablets and suspension in HIV-seropositive volunteers [abstract]. Clin Pharmacol Ther 1994;55:192.
19. DeAngelis DV, Long JD, Kanics LL, Woolley JL. High-performance liquid Chromatographic assay for the measurement of atovaquone in plasma. J Chromatogr 1994;652:211-9.
20. Beal SL, Sheiner LB. NONMEM users guide, NONMEM version IV. San Francisco: Project Group, University of California, San Francisco, 1994.
21. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320:565-70.
22. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990;48:10-7.
23. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996;42: 589-97.